[Anti-HIV drugs].

Anti-HIV drugs are fall into the following 5 categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and C-C chemokine receptor type 5 (CCR5) inhibitors. An appropriate combination of anti-HIV drugs, which is called ART (anti-retroviral therapy), can suppress HIV replication for prolonged periods. Since many anti-HIV drugs with relatively few side effects as well as high-potency have been developed recently, early initiation of ART is recommended regardless of the patients' CD4+ T-cell counts. However, ART does not lead to eradication or cure of HIV because of latent infection. Interruption of ART leads to a rapid rebound of viremia, necessitating life-long treatment. Thus, strategies to eradicate HIV from latently infected cells are urgently needed.

[1]  E. Clercq,et al.  Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. , 2009, International journal of antimicrobial agents.

[2]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[3]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.

[4]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[5]  H. Hatano,et al.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. , 2013, The Journal of infectious diseases.

[6]  Sebastian Bonhoeffer,et al.  The HIV coreceptor switch: a population dynamical perspective. , 2005, Trends in microbiology.

[7]  W. Sugiura,et al.  Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. , 2010, Antiviral research.

[8]  I. Mcintosh,et al.  Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme , 2007, Drug Metabolism and Disposition.

[9]  K. White,et al.  A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results , 2013, Journal of acquired immune deficiency syndromes.

[10]  D. Richman,et al.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Till Bärnighausen,et al.  Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment , 2013, Science.

[12]  Y. Pommier,et al.  Integrase inhibitors to treat HIV/Aids , 2005, Nature Reviews Drug Discovery.

[13]  Allan J. Hance,et al.  HIV Drug Resistance , 2004 .

[14]  J. Montaner,et al.  Ritonavir-boosted protease inhibitors in HIV therapy , 2011, Annals of medicine.

[15]  A. Engelman,et al.  The structural biology of HIV-1: mechanistic and therapeutic insights , 2012, Nature Reviews Microbiology.

[16]  J. Rockstroh,et al.  A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results , 2013, Journal of acquired immune deficiency syndromes.

[17]  G. McComsey,et al.  Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management , 2004, Journal of acquired immune deficiency syndromes.

[18]  Robert Craigie,et al.  HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer , 1991, Cell.

[19]  J. Levy.  Infection by human immunodeficiency virus--CD4 is not enough. , 1996, The New England journal of medicine.

[20]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial , 2012, The Lancet.